Advisors Capital Management LLC Lowers Holdings in United Therapeutics Corporation $UTHR

Advisors Capital Management LLC decreased its position in United Therapeutics Corporation (NASDAQ:UTHR) by 4.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,030 shares of the biotechnology company’s stock after selling 45 shares during the period. Advisors Capital Management LLC’s holdings in United Therapeutics were worth $318,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. XTX Topco Ltd purchased a new stake in United Therapeutics during the first quarter worth $313,000. Allianz Asset Management GmbH lifted its holdings in United Therapeutics by 96.9% during the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company’s stock worth $20,832,000 after buying an additional 33,254 shares during the period. LPL Financial LLC lifted its holdings in United Therapeutics by 77.3% during the first quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company’s stock worth $7,783,000 after buying an additional 11,007 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in United Therapeutics by 11.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company’s stock worth $1,129,000 after buying an additional 376 shares during the period. Finally, Concurrent Investment Advisors LLC purchased a new stake in shares of United Therapeutics during the 1st quarter valued at $227,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

Shares of UTHR opened at $405.02 on Friday. The business’s 50-day moving average is $318.53 and its two-hundred day moving average is $307.48. The company has a market capitalization of $18.27 billion, a P/E ratio of 15.81, a P/E/G ratio of 6.17 and a beta of 0.62. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $436.95.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $6.80 by ($0.39). The company had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.United Therapeutics’s revenue for the quarter was up 11.7% on a year-over-year basis. During the same period in the prior year, the business posted $5.85 earnings per share. Analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insider Activity

In other news, Director Tommy G. Thompson sold 4,560 shares of the firm’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $403.36, for a total transaction of $1,839,321.60. Following the sale, the director directly owned 8,480 shares in the company, valued at $3,420,492.80. This trade represents a 34.97% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 4,000 shares of the firm’s stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $397.23, for a total value of $1,588,920.00. Following the sale, the chief executive officer owned 130 shares in the company, valued at $51,639.90. This trade represents a 96.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 128,816 shares of company stock worth $45,836,113. 10.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

UTHR has been the subject of several analyst reports. Oppenheimer increased their price objective on United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a report on Friday, September 5th. Bank of America increased their price objective on United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a report on Tuesday, September 2nd. Wells Fargo & Company increased their price objective on United Therapeutics from $295.00 to $414.00 and gave the company an “equal weight” rating in a report on Wednesday, September 3rd. Cantor Fitzgerald increased their price objective on United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. decreased their price objective on United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a report on Tuesday, July 8th. Nine investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $438.85.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.